Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

BUY
$26.4 - $30.54 $52 - $61
2 Added 2.0%
102 $3,000
Q1 2022

May 10, 2022

BUY
$23.07 - $27.99 $2,307 - $2,799
100 New
100 $3,000
Q4 2021

Feb 11, 2022

SELL
$21.47 - $32.08 $196,944 - $294,269
-9,173 Closed
0 $0
Q2 2021

Aug 09, 2021

SELL
$18.78 - $25.15 $116,680 - $156,256
-6,213 Reduced 40.38%
9,173 $225,000
Q1 2021

Apr 28, 2021

BUY
$18.21 - $23.2 $278,358 - $354,635
15,286 Added 15286.0%
15,386 $286,000
Q4 2020

Feb 09, 2021

SELL
$15.39 - $22.1 $242,977 - $348,914
-15,788 Reduced 99.37%
100 $2,000
Q3 2020

Nov 02, 2020

BUY
$16.16 - $20.66 $13,897 - $17,767
860 Added 5.72%
15,888 $264,000
Q2 2020

Aug 11, 2020

SELL
$13.31 - $19.41 $44,548 - $64,965
-3,347 Reduced 18.21%
15,028 $291,000
Q1 2020

May 15, 2020

BUY
$13.06 - $21.24 $65 - $106
5 Added 0.03%
18,375 $265,000
Q4 2019

Feb 13, 2020

BUY
$17.29 - $21.74 $177,793 - $223,552
10,283 Added 127.15%
18,370 $375,000
Q3 2019

Oct 17, 2019

BUY
$19.51 - $24.28 $115,850 - $144,174
5,938 Added 276.31%
8,087 $158,000
Q2 2019

Aug 05, 2019

BUY
$21.47 - $37.33 $7,278 - $12,654
339 Added 18.73%
2,149 $48,000
Q4 2018

Jan 17, 2019

BUY
$27.94 - $44.61 $30,761 - $49,115
1,101 Added 155.29%
1,810 $53,000
Q3 2018

Nov 02, 2018

SELL
$38.6 - $46.12 $14,938 - $17,848
-387 Reduced 35.31%
709 $0
Q2 2018

Jul 24, 2018

BUY
$40.56 - $51.36 $23,443 - $29,686
578 Added 111.58%
1,096 $0
Q1 2018

May 03, 2018

BUY
$53.61 - $67.26 $10,400 - $13,048
194 Added 59.88%
518 $30,000
Q4 2017

Feb 02, 2018

BUY
$47.69 - $55.39 $15,451 - $17,946
324
324 $18,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.67B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.